-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $41

Benzinga·11/16/2026 15:16:41
Listen to the news
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $48 to $41.